State Street SPDR S&P Biotech ETF (XBI) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.47: the stock has moved about 47% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerState Street SPDR S&P Biotech ETF (XBI) trades at $144.12. The State Street SPDR S&P Biotech ETF (XBI) aims to mirror the performance of the S&P Biotechnology Select Industry Index. Sector: Financials.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for XBI: XBI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
State Street SPDR S&P Biotech ETF (XBI) Financial Services Profile
State Street SPDR S&P Biotech ETF (XBI) provides targeted exposure to the biotechnology sector of the S&P TMI, tracking a modified equal-weighted index. This ETF allows investors to strategically position themselves within the biotech industry, spanning large, mid, and small-cap stocks, offering a diversified yet focused investment vehicle.
What Is the Investment Thesis for XBI?
The State Street SPDR S&P Biotech ETF (XBI), with a market capitalization of $6.31 billion and a beta of 1.47, presents a targeted investment in the biotechnology sector. Its modified equal-weighted approach offers diversification across large, mid, and small-cap biotech companies. A key value driver is the potential for growth within the biotechnology industry, driven by innovation in drug development and increasing healthcare spending. Upcoming catalysts include potential breakthroughs in gene therapy and personalized medicine, which could significantly boost the valuations of companies within the index. However, potential risks include regulatory hurdles, clinical trial failures, and market volatility, all inherent to the biotech industry. Investors may want to evaluate these factors when evaluating XBI as part of their portfolio, recognizing the high-risk, high-reward nature of the biotechnology sector.
Based on FMP financials and quantitative analysis
XBI Key Highlights
Market Cap of $6.31B indicates substantial investment in the biotechnology sector through XBI.
- Beta of 1.47 suggests higher volatility compared to the overall market, typical for biotech investments.
- The ETF tracks the S&P Biotechnology Select Industry Index, providing focused exposure to the biotech industry.
- Modified equal-weighted index reduces concentration risk and allows exposure to smaller, high-growth biotech firms.
- No dividend yield reflects the growth-oriented nature of the biotechnology sector.
Who Are XBI's Competitors?
XBI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AIQ Global X - Artificial Intelligence & Technology ETF | $54.42 | -2.53% | $9.07B | — |
| BBIN JPMorgan BetaBuilders International Equity ETF | $74.04 | -1.44% | $6.47B | — |
| BBUS JPMorgan BetaBuilders U.S. Equity ETF | $129.05 | -1.95% | $9.43B | — |
| EWZ iShares MSCI Brazil ETF | $29.51 | -1.86% | $6.20B | — |
| FDL First Trust Morningstar Dividend Leaders Index Fund | $52.05 | -1.59% | $8.55B | — |
| BLK BlackRock, Inc. | $1169.21 | -0.97% | $181B | 59 5-pillar |
| BX Blackstone Inc. | $115.71 | -0.66% | $143B | 85 5-pillar |
| BAM Brookfield Asset Management | $50.37 | +0.22% | $80.5B | 79 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XBI's Key Strengths?
Diversified exposure to the biotechnology sector.
- Modified equal-weighted methodology reduces concentration risk.
- High liquidity and trading volume.
- Strong brand recognition as part of the SPDR ETF family.
What Are XBI's Weaknesses?
High beta indicates higher volatility compared to the overall market.
- Sector-specific focus limits diversification.
- Performance is highly dependent on the biotechnology industry's performance.
- No dividend yield may deter income-seeking investors.
What Are the Key Risks for XBI?
Clinical trial failures and regulatory setbacks.
- Market volatility and economic downturns.
- High research and development costs.
- Competition from other biotechnology companies.
- Changes in healthcare policy and reimbursement rates.
What Are XBI's Competitive Advantages?
- First-mover advantage in offering a biotechnology-focused ETF.
- Strong brand recognition as part of the SPDR ETF family.
- High liquidity and trading volume.
- Diversified exposure to the biotechnology sector.
What Does XBI Do?
The State Street SPDR S&P Biotech ETF (XBI) was created to replicate, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index. This index represents the biotechnology sub-industry within the broader S&P Total Market Index (TMI). XBI provides investors with a means to access a basket of stocks specifically focused on biotechnology companies. The ETF employs a modified equal-weighting methodology, which differentiates it from market capitalization-weighted ETFs. This approach aims to reduce concentration risk by giving similar weight to companies regardless of their size, potentially offering exposure to smaller, high-growth biotech firms alongside established industry players. Since its inception, XBI has become a popular tool for investors seeking to express a view on the biotechnology sector. The fund's holdings span a range of companies involved in various aspects of biotechnology, including drug discovery, development, and manufacturing. By tracking the S&P Biotechnology Select Industry Index, XBI offers a relatively liquid and transparent way to invest in this dynamic and often volatile sector. The ETF's structure allows for both strategic, long-term investments and tactical, short-term positions, catering to a diverse range of investment strategies. State Street, the issuer of the SPDR ETFs, is one of the world's largest asset managers, providing investors with confidence in the fund's management and operational efficiency. XBI's focus on the biotechnology sector makes it a specialized tool within the broader landscape of sector-specific ETFs.
What Products and Services Does XBI Offer?
- Tracks the performance of the S&P Biotechnology Select Industry Index.
- Provides exposure to a diversified portfolio of biotechnology companies.
- Employs a modified equal-weighted methodology to reduce concentration risk.
- Offers investors a liquid and transparent way to invest in the biotech sector.
- Allows for both strategic, long-term investments and tactical, short-term positions.
- Provides access to companies involved in drug discovery, development, and manufacturing.
How Does XBI Make Money?
- Tracks the S&P Biotechnology Select Industry Index.
- Generates revenue through management fees charged to investors.
- Offers a diversified investment in the biotechnology sector through a single ETF.
- Utilizes a modified equal-weighted approach to mitigate concentration risk.
What Industry Does XBI Operate In?
The biotechnology industry is characterized by rapid innovation, high research and development costs, and significant regulatory oversight. The market is driven by advancements in genomics, personalized medicine, and novel drug therapies. The State Street SPDR S&P Biotech ETF (XBI) operates within this dynamic landscape, offering investors exposure to a broad range of companies, from established players to emerging innovators. Competitors like AIQ, BBIN, BBUS, EWZ, and FDL offer alternative approaches to investing in the biotechnology and related sectors, with varying degrees of diversification and focus.
Who Are XBI's Key Customers?
- Institutional investors seeking exposure to the biotechnology sector.
- Retail investors looking for a diversified investment in biotech stocks.
- Financial advisors seeking to allocate client portfolios to the biotech industry.
- Hedge funds and other sophisticated investors trading on short-term biotech trends.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
XBI Financials
Bull Case vs Bear Case
Bull Case
- Diversified exposure to the biotechnology sector.
- Modified equal-weighted methodology reduces concentration risk.
- High liquidity and trading volume.
- Strong brand recognition as part of the SPDR ETF family.
Bear Case
- High beta indicates higher volatility compared to the overall market.
- Sector-specific focus limits diversification.
- Performance is highly dependent on the biotechnology industry's performance.
- No dividend yield may deter income-seeking investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
XBI Latest News
-
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
benzinga · Nov 16, 2026
-
Three FDA Decisions Loom After Summit’s Rejection — Capricor, Savara, Alzheimer’s Data Top Biotech’s Watchlist
Stocktwits · Nov 16, 2026
-
While AI hogged the headlines, 1 overlooked sector beat the S&P 500 — and its top stock is up 700%+ this year
Moneywise · Nov 13, 2026
-
Bank of America Sees Up to 95% Upside in 2 Stocks
GuruFocus.com · Nov 12, 2026
XBI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for XBI.
Price Targets
Wall Street price target analysis for XBI.
XBI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for XBI; grades run from A+ (80-100) to F (below 30).
Latest News
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
Three FDA Decisions Loom After Summit’s Rejection — Capricor, Savara, Alzheimer’s Data Top Biotech’s Watchlist
While AI hogged the headlines, 1 overlooked sector beat the S&P 500 — and its top stock is up 700%+ this year
Bank of America Sees Up to 95% Upside in 2 Stocks
What Investors Ask About State Street SPDR S&P Biotech ETF (XBI) — Financials
What are the main risks for XBI?
The State Street SPDR S&P Biotech ETF (XBI) faces several key risks inherent to the biotechnology sector. Clinical trial failures and regulatory setbacks can significantly impact the valuations of companies within the ETF.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Data provided for informational purposes only.
- Biotechnology sector is inherently volatile and subject to regulatory risks.